Abstracts tagged "Disease Activity"

Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 175 • 2016 ACR/ARHP Annual Meeting
Suppressor of Cytokine Function One (SOCS1) Is Elevated in Non-Classical Monocytes and Correlates with Disease Activity in Systemic Lupus Erythematosus Patients
Talha Khawar¹, Jessica Cooke², Nasim Daoud³, Vaneet Sandhu⁴, Willie Davis², Warren Peters⁵, Karina Marianne D. Torralba⁶, Michelle T. Ngo⁶, Sheila Lezcano¹, Kimberly J. Payne^7,8 and Abby Jones Weldon⁹, ¹Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ²Department of Pharmaceutical and Administrative Sciences, School of Pharmacy, Loma Linda University, Loma Linda, CA, ³Division of Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁴Division of Rheumatology, Loma Linda University, Loma Linda, CA, ⁵Department of Preventative Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, ⁶Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA, ⁹Loma Linda University, Loma Linda, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease resulting from dysregulated innate and adaptive immune components that result in an inflammatory response. Cytokines produced…
Abstract Number: 540 • 2016 ACR/ARHP Annual Meeting
The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting
Sergio Schwartzman¹, Keith Knapp^2,3, Gary Craig^2,3, Karen Ferguson^2,3 and Discus Analytics, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest PLLC., Spokane, WA, ³Discus Analytics LLC., Spokane, WA
The Importance of Outcome Measures in Rheumatoid Arthritis - Validity of the RAPID3 (Routine Assessment of Patient Index Data 3) in a United States “Real…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 1370 • 2016 ACR/ARHP Annual Meeting
Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Silvia Rosina¹, Alessandro Consolaro¹, Pieter van Dijkhuizen¹, Kiran Nistala², Nicola Ruperto¹, Clarissa Pilkington³ and Angelo Ravelli¹, ¹Rheumatology, Giannina Gaslini Institute, Genova, Italy, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom
Background/Purpose: JDM is a multisystem vasculopathic disease that primarily affects the skin and muscles. Most tools for assessment of disease activity in JDM are lenghty,…
Abstract Number: 1545 • 2016 ACR/ARHP Annual Meeting
Vitamin D Insufficiency in Patients with Rheumatoid Arthritis and Healthy Controls and Correlation Between Vitamin D Levels and Disease Activity and Disability in RA Patients
Bhupendra Vaishnav^1,2, Bhowmik Meghnathi^1,3, Abhishek Patil¹, Sundeep Upadhyaya¹, S J Gupta¹ and Rohini Handa¹, ¹Rheumatology, Indraprastha Apollo Hospitals, New Delhi, India, ²Rheumatology, Rajiv Gandhi Superspeciality Hospital, Delhi, India, ³Rheumatology B, Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France
Background/Purpose: Lower serum vitamin D levels have been shown to be associated with various autoimmune disorders including Rheumatoid Arthritis (RA). We undertook this study to…
Abstract Number: 1823 • 2016 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with both genetic and environmental contributions to disease etiology. Patients with different ancestral backgrounds have different…
Abstract Number: 2466 • 2016 ACR/ARHP Annual Meeting
Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
Isabel Castrejón¹, Martin J. Bergman², Kathryn Gibson^3,4, Yusuf Yazici⁵, Joel Block⁶ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Taylor Hospital, Ridley Park, PA, ³Liverpool Hospital, Sydney, Sydney, Australia, ⁴Ingham Research Institute, Liverpool, Australia, ⁵Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Remission rates in patients with rheumatoid arthritis (RA) according to RAPID3 (routine assessment of patient index data) are reported at 25% in France1 and…
Abstract Number: 2675 • 2016 ACR/ARHP Annual Meeting
Essdai, Clinessdai and DAS Scoring at Diagnosis of Primary Sjogren Syndrome: Association with the Development of Hematologic and Solid Neoplasias in 1301 Patients
Soledad Retamozo^1,2, Belchin Kostov³, Guadalupe Fraile⁴, Daniel Caravia-Durán⁵, Brenda Maure⁶, Francisco Javier Rascón⁷, Mónica Zamora⁸, Arnau Casanovas⁹, Miguel Lopez-Dupla¹⁰, Mar Ripoll¹¹, Blanca Pinilla¹², Eva Fonseca¹³, Miriam Akasbi¹⁴, Gloria De la Red¹⁵, Miguel-Angel Duarte-Millán¹⁶, Patricia Fanlo Mateo¹⁷, Pablo Guisado¹⁸, Roberto Pérez-Alvarez¹⁹, Sandra Rodríguez-Rodríguez²⁰, César Morcillo²¹, Iratxe Jiménez-Heredia²², Alberto Gato²³, Jordi Gratacós¹, Isabel Sánchez-Berná¹, Manuel Ramos-Casals^24,25, Pilar Brito-Zerón^1,26 and SS Registry GEAS-SEMI, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Primary Care Research Group, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ⁵Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁶Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo, Vigo, Spain, ⁷Department of Internal Medicine, Hospital Son Espases, Palma de Mallorca, Palma de Mallorca, Spain, ⁸Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Granada, Spain, ⁹Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Sadabell, Spain, ¹⁰Department of Internal Medicine, Hospital Joan XXIII, Tarragona, Tarragona, Spain, ¹¹Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Madrid, Spain, ¹²Department of Internal Medicine, Hospital Gregorio Marañón, Madrid, Madrid, Spain, ¹³Department of Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ¹⁴Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Madrid, Spain, ¹⁵Department of Internal Medicine, Hospital Esperit Sant, Badalona, Badalona, Spain, ¹⁶Department of Internal Medicine, Hospital de Fuenlabrada, Fuenlabrada, Spain, ¹⁷Department of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain, ¹⁸Department of Internal Medicine, Complejo Hospitalario Ruber Juan Bravo, Madrid, Madrid, Spain, ¹⁹Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ²⁰Department of Internal Medicine, Hospital de Salamanca, Salamanca, Salamanca, Spain, ²¹Department of Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ²²Department of Internal Medicine, Hospital de Sagunto, Valencia, Valencia, Spain, ²³Department of Internal Medicine, Complejo Hospitalario Albacete, Albacete, Albacete, Spain, ²⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ²⁶Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: To score systemic activity at diagnosis of primary Sjogren syndrome (pSS) using the European systemic activity indexes ESSDAI, clinESSDAI and DAS in order to…
Abstract Number: 2833 • 2016 ACR/ARHP Annual Meeting
Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE
Helena Tydén¹, Christian Lood², Andreas Jönsen³, Birgitta Gullstrand⁴, Bjorn Dahlback⁵ and Anders A. Bengtsson³, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁴Department of Clinical Sciences, Division of Rheumatology, Lund University, Lund, Sweden, ⁵Department of Translational Medicine, Division of Clinical Chemistry, Lund University, Skane University Hospital Malmö, Malmö, Sweden
Background/Purpose: Human apoM is a 25kDa apolipoprotein present in 5% of HDL particles in plasma. In mouse models, apoM is antiatherogenic and vasculoprotective and…
Abstract Number: 3186 • 2016 ACR/ARHP Annual Meeting
Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis and Levels of Discordance According to Disease Activity: A Multicenter European Study
Carole Desthieux¹, Benjamin Granger², Andra Rodica Balanescu³, P Balint⁴, Jürgen Braun⁵, Juan Canete⁶, Turid Heiberg⁷, Philip S. Helliwell⁸, Umut Kalyoncu⁹, Tore K Kvien¹⁰, Uta Kiltz⁵, Dora Niedermayer¹¹, Kati Otsa¹², Rossana Scrivo¹³, Josef Smolen¹⁴, Tanja A. Stamm¹⁵, Douglas J. Veale¹⁶, Kurt de Vlam¹⁷, Maarten de Wit¹⁸ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Biostatistics, Pitié Salpêtrière Hospital, Paris, France, ³Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ⁴Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain, ⁷Oslo University Hospital, Oslo, Norway, ⁸NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹Hacettepe University, Ankara, Turkey, ¹⁰Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹PsAID taskforce, EULAR, Zurich, Switzerland, ¹²Rheumatology, Tallinn Central Hospital, Tallinn, EE, ¹³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁴Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁵Internal Medicine III, Vienna Medical University, Vienna, Austria, ¹⁶Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland, ¹⁷Katholieke Universiteit Leuven, Leuven, Belgium, ¹⁸Medical Humanities, VU Medical Centre, Amsterdam, Netherlands
Background/Purpose: In the management of chronic diseases, recommendations insist on the need to work in partnership with the patient. Patient-physician discordance in global assessment of…
Abstract Number: 185 • 2016 ACR/ARHP Annual Meeting
The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Faye A H Cooles¹, Amy E. Anderson¹, Dennis W Lendrem¹, Julie Norris¹, Arthur G. Pratt¹, Catharien M U Hilkens² and John D Isaacs³, ¹Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: Type 1 interferons, such as interferon-α, are of increasing interest in autoimmunity due to their pleiotropic effects on the immune system. Approximately 20-30% of…
Abstract Number: 551 • 2016 ACR/ARHP Annual Meeting
Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis
Craig Wiesenhutter, Coeur d'Alene Arthritis Clinic, Coeur D Alene, ID; University of Washington School of Family Medicine, Seattle, ID
Background/Purpose: Treating rheumatoid arthritis (RA) patients to target (T2T) has been shown to result in better outcomes in patients with relatively recent onset RA. The…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 1374 • 2016 ACR/ARHP Annual Meeting
Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Timothy B. Niewold³, Ann M Reed⁴ and CARRA Investigators, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Duke University, Durham, NC
Background/Purpose: Determinants of changes in disease activity among patients with juvenile dermatomyositis (JDM) are unknown. Our objective was to develop scores to predict changes in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].